Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$89.02M$89.02M+251.1% vs Q1 2020 Net Income$27.90M$27.90MN/M vs Q1 2020 EPS Diluted$0.19$0.19N/M vs Q1 2020 Operating Income$50,735,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Free Cash Flowderived$58,026,000N/M Margins · derivedOperating margin57.0%+69.7 pt vs Q1 2020
Net margin31.3%+55.4 pt vs Q1 2020
ended Mar 31, 2021 · filed May 10, 2021 · 40 d after period end